Molecular Biology Core
分子生物学核心
基本信息
- 批准号:10618376
- 负责人:
- 金额:$ 22.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-05 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAntibody FormationApplications GrantsArkansasAwardCenters of Research ExcellenceCloningCore FacilityDNADNA Sequencing FacilityDNA biosynthesisDNA sequencingDataDedicationsDoctor of PhilosophyEnsureEquationEquipmentFee-for-Service PlansFeesFlow CytometryFundingGelGenesGenomic LibraryGenomicsGoalsGrowthHuman ResourcesImmunologyInflammatoryInflammatory ResponseInstitutionInvestmentsLaboratory PersonnelMaintenanceManuscriptsMedicalMedicineMethodsMicrobial Genome SequencingMicrobiologyModernizationMolecular BiologyOpportunistic InfectionsPathogenesisPhasePreparationProteinsRNARecoveryResearchResearch InfrastructureResearch PersonnelResourcesSamplingScienceScientistService delivery modelServicesSideSupervisionTechnologyTimeTrainingUniversitiesValidationWestern BlottingWorkbasecellular imagingcollegecostequipment acquisitiongenome-wideinstrumentinstrumentationmicrobialmicroscopic imagingnext generationnext generation sequencingoperationpathogenprogramsprotein expressionprotein purificationquantitative imagingresponsesuccesstooluser-friendlyvoucher
项目摘要
PROJECT SUMMARY/ABSTRACT
In Phases I and II, the Center for Microbial Pathogenesis and Host Inflammatory Responses (CMPHIR)
established and maintained a Research and Technical Advancement Core to fill experimental gaps in the
resources available in institutional cores maintained by the UAMS College of Medicine. One of these was a DNA
Sequencing Core. However, the capability of this core was limited to single-gene sequencing. While this was an
important and necessary service, it was not sufficient, particularly in an era of genomic and next-generation
sequencing technology. Thus, the CMPHIR also invested heavily in augmenting the resources available in the
existing DNA Sequencing Core. We accomplished this task, and, in Phase III, we propose to integrate these
services under the common umbrella of a Molecular Biology Core (Core B) capable of providing CMPHIR and
other UAMS investigators with the resources they need, particularly with respect to the pathogen side of the
host–pathogen equation. The activities of Core B include enhancing the capability of obtaining high-quality RNA,
DNA, and protein samples for analysis; high-throughput single-gene sequencing using conventional Sanger
methods; next-generation sequencing of microbial genomes and genomic libraries; protein expression and
purification; and antibody production. The proposed Core B will be supported through a combination of CMPHIR
funding and continued institutional support. Daily operations will be supervised by Dr. Jon S. Blevins, Director,
who will work with 2 full-time technicians. One of these technicians will have primary responsibility for the DNA
component of Core B, while the other will have primary responsibility for the protein component. To ensure
consistency and promote self-sustainability, Core B instruments will be operated by these technicians on behalf
of CMPHIR and UAMS investigators on a fee-for-service basis. This will allow us to recover a significant
proportion of the costs and thereby ensure the ability to upgrade and maintain the equipment in this core as
needed as we move forward into Phase III and beyond.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jon Scott Blevins其他文献
Jon Scott Blevins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jon Scott Blevins', 18)}}的其他基金
Cyclic di-AMP-dependent signaling in tickborne relapsing fever Borrelia
蜱传回归热伯氏疏螺旋体中的环状双 AMP 依赖性信号传导
- 批准号:
10679004 - 财政年份:2022
- 资助金额:
$ 22.8万 - 项目类别:
Cyclic di-AMP-dependent signaling in tickborne relapsing fever Borrelia
蜱传回归热伯氏疏螺旋体中的环状双 AMP 依赖性信号传导
- 批准号:
10503309 - 财政年份:2022
- 资助金额:
$ 22.8万 - 项目类别:
Cyclic di-GMP Second Messenger Signaling in the Tickborne Relapsing Fever Spirochete, Borrelia turicatae
蜱传回归热螺旋体、Borrelia turicatae 中的环状 di-GMP 第二信使信号传导
- 批准号:
10378138 - 财政年份:2021
- 资助金额:
$ 22.8万 - 项目类别:
Rrp2-dependent gene regulation in Borrelia burgdorferi
伯氏疏螺旋体中 Rrp2 依赖性基因调控
- 批准号:
9090056 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
Rrp2-dependent gene regulation in Borrelia burgdorferi
伯氏疏螺旋体中 Rrp2 依赖性基因调控
- 批准号:
8951367 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
RpoS-mediated virulence regulation in Borrelia burgdorferi
RpoS 介导的伯氏疏螺旋体毒力调控
- 批准号:
8722793 - 财政年份:2013
- 资助金额:
$ 22.8万 - 项目类别:
RpoS-mediated virulence regulation in Borrelia burgdorferi
RpoS 介导的伯氏疏螺旋体毒力调控
- 批准号:
7992838 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
RpoS-mediated virulence regulation in Borrelia burgdorferi
RpoS 介导的伯氏疏螺旋体毒力调控
- 批准号:
8259762 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
RpoS-mediated virulence regulation in Borrelia burgdorferi
RpoS 介导的伯氏疏螺旋体毒力调控
- 批准号:
8449257 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 22.8万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 22.8万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 22.8万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 22.8万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 22.8万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 22.8万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 22.8万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 22.8万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 22.8万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 22.8万 - 项目类别: